{"id":4250,"date":"2025-05-31T23:07:50","date_gmt":"2025-05-31T23:07:50","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/05\/31\/trodelvy-keytruda-breast-cancer-gilead-merck-results\/"},"modified":"2025-05-31T23:07:50","modified_gmt":"2025-05-31T23:07:50","slug":"trodelvy-keytruda-breast-cancer-gilead-merck-results","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/05\/31\/trodelvy-keytruda-breast-cancer-gilead-merck-results\/","title":{"rendered":"STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows"},"content":{"rendered":"<p>    STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>CHICAGO \u2014 A treatment that combines two different types of cancer-fighting medicines \u2014 Gilead Sciences\u2019 Trodelvy with Merck\u2019s Keytruda \u2014 reduced the risk of tumor progression by more than one-third in women with an aggressive form of breast cancer.\u00a0<\/p>\n<p>The results reported Saturday from the randomized Phase 3 study called ASCENT-04 could lead to a new treatment option for patients with newly diagnosed, metastatic, triple-negative breast cancer, experts said.\u00a0<\/p>\n<p>Gilead, which conducted the study, could also benefit from a boost in Trodelvy sales at a time when it faces competition from a similar drug made by AstraZeneca and Daiichi Sankyo.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/05\/31\/trodelvy-keytruda-breast-cancer-gilead-merck-results\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/05\/31\/trodelvy-keytruda-breast-cancer-gilead-merck-results\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows CHICAGO \u2014 A treatment that combines two different types of cancer-fighting medicines \u2014 Gilead Sciences\u2019 Trodelvy with Merck\u2019s Keytruda \u2014 reduced the risk of tumor progression by more than one-third in women with an aggressive form of breast cancer.\u00a0 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2733,2194,2154,2159,2155,2152],"tags":[2150],"class_list":["post-4250","post","type-post","status-publish","format-standard","hentry","category-asco","category-biotech","category-biotechnology","category-cancer","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4250"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=4250"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/4250\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=4250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=4250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=4250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}